News

Despite treatment advances in pulmonary hypertension (PH) over the last two decades, the age-adjusted PH-related death rate in the U.S. increased annually between 1999 and 2019, with mortality climbing by nearly 2% each year, a new study found. The simultaneous presence of PH and disease of the left side…

Switching from weekly infusions of levosimendan to a daily oral version of the experimental medication was well-tolerated among people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to new trial data. That data, from the open-label extension phase of the HELP Phase 2 clinical…

Treatment with sotatercept, given in addition to standard therapies, significantly improves exercise capacity in people with pulmonary arterial hypertension (PAH). Those are the new findings of a pivotal Phase 3 clinical trial called STELLAR, which tested the therapy’s safety and efficacy in improving PAH patients’ ability to walk. Now,…

Less oxygen uptake during exercise increases the risk of clinical worsening in people with pulmonary hypertension (PH) due to a heart defect called pulmonary artery stenosis (PAS), a study shows. Data also showed the chance of recovery was generally poor for this subgroup of patients and it was common…

Two weeks of aerobic exercise improved blood flow parameters and survival in a rat model of pulmonary arterial hypertension (PAH), and altered the energy usage of cells in the heart, a new study reports. “Our data support the beneficial effect of exercise training in this clinical setting, as two…

A high dose of Tyvaso (inhaled treprostinil) — at least nine breaths four times per day — is more effective at preventing clinical worsening than lower doses for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a new study indicates. “This analysis further reinforces that [Tyvaso]…

A blood test for angiopoietin-2 (Ang-2), a protein associated with forming new blood vessels, may predict treatment outcomes in people with chronic thromboembolic pulmonary hypertension (CTEPH), a study showed. Researchers found that the protein’s level was significantly higher in the bloodstream of patients with this rare form of…

The U.S. Food and Drug Administration (FDA) has accepted a proposal from Bellerophon Therapeutics to reduce the size of a Phase 3 clinical trial that’s testing its INOpulse device on people with pulmonary fibrosis (PF) at risk of pulmonary hypertension (PH). The change, made based on analyses from…

The National Institutes of Health (NIH) has granted Aqualung Therapeutics two three-year awards totaling $4.8 million to develop ALT-100, a humanized monoclonal antibody, for the treatment of pulmonary arterial hypertension (PAH) and inflammatory bowel disease (IBD). ALT-100 is designed to address and prevent inflammation in severe inflammatory…

Levels of the Wnt inhibitory factor 1 (WIF-1) protein were elevated in the blood of people with pulmonary hypertension (PH) associated with left-sided heart failure, according to a new study. WIF-1 was linked with higher levels of NT-proBNP — a marker of heart failure — as well as several…

Treatment with Pulnovo Medical‘s pulmonary artery denervation (PADN) device improved exercise capacity, blood flow dynamics, and clinical outcomes for pulmonary arterial hypertension (PAH) patients in a clinical trial called PADN-CFDA, the company announced. “The PADN-CFDA results are very important because this was an adequately powered randomized controlled trial,…

Digital health company Eko has been awarded $2.7 million from the National Institutes of Health (NIH) to develop an artificial intelligence (AI)-based algorithm that can detect pulmonary hypertension (PH) and classify its severity. The algorithm will analyze data from two common, noninvasive heart tests collected via Eko’s digital smart…